louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05679063: Therapeutic Exercise and Education in Neurophysiology of Pain in the Quality of Life of Women With Endometriosis
Official title: Therapeutic Exercise and Education in Neurophysiology of Pain in the Quality of Life of Women With Endometriosis: Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endometriosis
Lead sponsor: University of Valladolid
Sponsor class: OTHER
First posted: 2023-01-10
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Trough a randomization program, participants will be assigned to the treatment group or the control group.
Primary purpose: TREATMENT

Brief summary: The objective of this study will be to evaluate treatment using ET exercise and pain education in women with endometriosis to achieve improvement in quality of life.

Detailed description: A study will be carried out whose objective is to improve the quality of life in women with endometriosis through a program of therapeutic exercise and education in the neurophysiology of pain. Also as secondary variables will be observed: menstrual symptoms, sexual function, and abdominal wall thickness measured with ultrasound.

Eligibility criteria: Inclusion Criteria:

* Women of reproductive age between 18 and 45 years.
* Women with a medical diagnosis of endometriosis.
* Women with visual analog scale (EVA) between 4 and 10 (moderate-severe pain) during the last 3 months in the suprapubic area, abdomen or perineum both continuously and intermittently.

Exclusion Criteria:

* Women who must have surgery during the study.
* Women who have undergone abdominal or pelvic surgery or who have given birth (vaginal or cesarean) in the last 6 months.
* Women who are pregnant or planning a pregnancy.
* Women with uncorrected pacemakers or coagulopathies, severe comorbid disorder, cancer (in the last 5 years or at present), severe mental disorders, or neuropathies affecting the nerves of the pelvis or lower extremities.
* Physiotherapy treatments or treatments related to pathology or study areas 15 days prior to the beginning of the study.
* Variations in medication in the 3 months prior to the start of the stud

Primary outcomes:
measure: Changes in quality of life perception assessed using EUROQuOL 5D - 5L
timeFrame: Baseline, Up to 1 month, Up to 3 months.
Secondary outcomes:
measure: Abdominal wall muscle thickness
timeFrame: Baseline, Up to 1 month, Up to 3 months
measure: Sexual Function assessed usinf Female Sexual Function Index (IFSF)
timeFrame: Baseline, Up to 1 month, Up to 3 months
measure: Symptoms associated with menstruation assessed using CVM-22 (quality of life related to menstruation)
timeFrame: Baseline, up to 1 month, up to 3 months
Other outcomes:
Locations:
city: Soria
country: Spain
facility: SBFisioterapia
Study officials:
affiliation: University of Valladolid
name: SANDRA JIMENEZ, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00315263: Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology
Official title: Genomics, SNPs, and Clinical Neonatology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Disease
Brain Injury
Necrotizing Enterocolitis
Respiratory Failure
Keywords: DNA
Genomics
SNPs
Neonatology
Chronic Lung Disease
Periventricular Brain Injury
Hypoxic Respiratory Failure
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
Collaborators: name: University of Kansas
First posted: 2006-04-18
Enrollment: 63
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Intensive Care Nursery

Brief summary: This research seeks to establish a neonatal DNA Tissue Bank to find out if differences in small segments of DNA predispose babies to Chronic Lung Disease (CLD), Periventricular Brain Injury (PVI), Necrotizing Enterocolitis (NEC), or Hypoxic Respiratory Failure (HRF).

Detailed description: This genetic predisposition study does not involve investigational drugs, devices, or treatments. Our broad goal is to identify genomic factors, which contribute to the development or exacerbation of common and critical illnesses that affect preterm and near-term infants. We seek to accomplish this goal in the following ways:

* First: to test candidate gene DNA variations and link already identified single nucleotide polymorphisms (SNPs) producing functional alterations to the risk of clinically important disorders.
* Second: to utilize a whole-genomic approach to identify SNPs not previously linked to the risk of development or progression of neonatal disorders.

Eligibility criteria: Inclusion Criteria:

* Less than 34 weeks gestation and less than 1500 g at birth
* Greater than or equal to 36 weeks gestation and either with hypoxic respiratory failure or with mild respiratory distress never requiring assisted ventilation

Exclusion Criteria:

* Life threatening anomalies of any organ system (e.g., cardiac, thoracic, lethal, or non-lethal chromosomal abnormalities)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Children's Mercy Hospitals and Clinics
state: Missouri
city: Kansas City
country: United States
facility: Truman Medical Center
state: Missouri
Study officials:
affiliation: Children's Mercy Hospital Kansas City
name: William E Truog, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02458963: IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS
Official title: In Vitro Fertilization Versus Gonadotropin Therapy in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Infertility
Polycystic Ovarian Syndrome
Keywords: PCOS
Clomiphene citrate resistant
Gonadotropin
IVF
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2015-06-01
Enrollment: 0
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of in vitro fertilization (IVF) versus gonadotropin therapy in infertile women having clomiphene citrate (CC) resistant polycystic ovarian syndrome (PCOS).

Detailed description: Women will be randomly divided into two groups; IVF group and gonadotropin group. Women in the IVF group will undergo one full IVF cycle. Women in the gonadotropin group will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.

Eligibility criteria: Inclusion Criteria:

* Infertile women with PCOS as defined by the Rotterdam criteria.
* CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).

Exclusion Criteria:

* Age \< 20 or \> 35 years.
* Presence of any infertility factor other than anovulatory PCOS.
* Previous history of ovarian surgery or surgical removal of one ovary.
* Previous exposure to cytotoxic drugs or pelvic irradiation.
* Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.
* Metabolic or hormonal abnormalities.

Primary outcomes:
measure: Live birth rate
timeFrame: 9 months
Secondary outcomes:
measure: Clinical pregnancy rate
timeFrame: 6-8 weeks gestational age
measure: Multifetal pregnancy rate
timeFrame: 12 weeks gestational age
measure: Miscarriage rate
timeFrame: 12 weeks gestational age
measure: Incidence of early ovarian hyperstimulation syndrome (OHSS)
timeFrame: Within 9 days of final triggering of oocyte maturation
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Fertility Care Unit (FCU) in Mansoura University Hospital
state: Dakahlia
city: Mansoura
country: Egypt
facility: Private fertility care centers
state: Dakahlia
Study officials:
affiliation: Mansoura University
name: Ahmed Gibreel, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Mansoura University
name: Mohamed S Abdelhafez, Dr
role: STUDY_DIRECTOR
References:
Clinical trial NCT03127163: Intraestromal Corneal Ring in Mild Keratoconus
Official title: Intrastromal Corneal Ring Was Effective for the Treatment of Mild Keratoconus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cornea
Eye Diseases
Keratoconus
Ophthalmological Disorder
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2017-04-25
Enrollment: 65
Sex: ALL
Minimum age (years): 17
Maximum age (years): 47
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Intraestromal corneal ring
Primary purpose: TREATMENT

Brief summary: To determine whether the implantation of an intrastromal corneal ring is an effective treatment for a homogeneous group of mild keratoconus patients.

Detailed description: A group of 65 patients with mild keratoconus were implanted with a Ferrara ring in a single eye. Six months after surgery, the aberrations were measured and the visual function was determined using clinical indices. The aberrations, especially comatic aberration (coma), were measured independently.

Eligibility criteria: Inclusion Criteria:

* Investigators used the Amsler-Krumeich classification and included only patients classified as grade I or II.

Exclusion Criteria:

* Investigators excluded patients with central corneal scarring, with other eye disorders, or with previous ocular surgery. We also excluded patients with a history of herpes infection, keratitis, corneal dystrophies, diagnoses of autoimmune diseases, systemic connective tissue disorders, or acute keratoconus.

Primary outcomes:
measure: Aberrations were measured and the visual function was determined using clinical indices.
timeFrame: 3 months after surgery
Secondary outcomes:
measure: UCVA
timeFrame: 3 months after surgery
measure: BCVA
timeFrame: 3 months after surgery
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Hospital das Clínicas
state: SP
Study officials:
affiliation: São Paulo University investigator
name: Mário Lima, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02760563: 18611 - Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-05-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing; Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female.
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form).
* Signed and dated Informed Consent Form.
* Signed and dated HIPAA Form (Health Insurance Portability and Accountability Act).
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose).

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnosed by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma, diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01400763: Lutein Bioavailability From Fresh and Dried Beverages
Official title: Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Macular Pigment
Keywords: focus of study
Lead sponsor: Wageningen University
Sponsor class: OTHER
First posted: 2011-07-22
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Macular pigment is composed primarily of the xanthophylls lutein and zeaxanthin, which are members of the carotenoid family. Epidemiological evidence indicates that a higher intake of lutein and zeaxanthin is associated with a lower risk to develop age-related macular degeneration (AMD). The lipid matrix of an egg yolk is an excellent vehicle for the efficient absorption of dietary lutein and it is possible to increase the natural lutein concentration in an egg yolk. A fresh lutein-enriched egg yolk beverage has been produced using these lutein-enriched egg-yolks. However, this beverage has a limited shelf life of maximum three weeks. Drying this fresh beverage extents the shelf live, however, this should be without loosing its functional properties concerning lutein bioavailability. At WUR-FBR two types of drying procedures have been evaluated resulting in two different dried product formulations, which need to be tested. The question is, whether the lutein bioavailability is not affected by different drying procedures.


Eligibility criteria: Inclusion Criteria:

* age 18-35 years
* BMI 18-25 kg/m2
* body weight should be stable for ≥6 months (with no weight gain/loss \> 3 kg)

Exclusion Criteria:

* use of medication except incidental use of pain killers
* pulmonary inhalation medication and except usage of the contraceptive pill
* chronic diseases such as IBD or other stomach or bowel diseases
* not willing to discontinue consumption of vitamin supplements
* allergic to cow milk / dairy products/ eggs/ egg-rich products
* vegetarians
* smoking
* pregnant or breastfeeding women
* having donated blood (as blood donor) within 1 month prior to the screening
* visit or planning to do so during the study
* impossible or difficult venapuncture

Primary outcomes:
measure: Serum lutein concentration
timeFrame: six weeks after intervention
Secondary outcomes:
measure: Serum lipid concentrations
timeFrame: six weeks after intervention
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00173563: Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children
Official title: Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Keywords: Immunology
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2005-09-15
Enrollment: 10
Sex: ALL
Minimum age (years): 2
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: Severe acute respiratory syndrome (SARS) is a new emerging infectious disease. Its pathogen is a newly discovered coronavirus (SARS-CoV). The clinical course can be classified to 3 stages: viral replication phase, hyperimmune reactive phase, and pulmonary destruction phase. Human monocyte plays a critical role in the initiation of immune response in defending the intracellular pathogens (eg viruses). Monocytes can engulf viruses and present the viral antigens in the major histocompatibility (MHC) molecule to the cell surface to initiate T lymphocyte response. Monocytes also secrete various cytokines to modulate immune response. SARS-CoV is a mutant of animal virus to cause human disease and is able to cause unusual severe respiratory illness. It is suggested the unusual severe disease is due to the intense immune reaction.

The investigators will harvest human monocytes from healthy adult and children blood donors. Monocytes would be cultured and infected by SARS-CoV. The change of viral load is monitored after infection. Cytokines secreted by monocytes after infection are also measured. The difference of monocyte cytokine secretion is compared between adults and children. The study is to verify the SARS-CoV infectivity of human monocytes and prove the unusual severity caused by SARS-CoV is related to viral-induced dysregulation of cytokine responses. The results may also clarify why adults tend to have a more severe illness compared with children.


Eligibility criteria: Inclusion Criteria:

* Healthy adults aged 20 to 50 years old
* Healthy children aged 2 to 5 years old

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Department of pediatrics, National Taiwan University Hospital
name: Luan-Yin Chang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03231163: Physiological and Perceptual Effects of Music on Resting Metabolic Rate (RMR)
Official title: Physiological and Perceptual Effects of Music on Resting Metabolic Rate (RMR)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolism
Lead sponsor: Old Dominion University
Sponsor class: OTHER
First posted: 2017-07-27
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of the study is to determine whether music has any effect on resting metabolic rate (RMR), which is the amount of energy expended at rest. There is currently conflicting research on how music affects RMR. One problem with RMR testing is that participants often fall asleep during the test. There can be a 5-10% difference in the metabolic rate between rest and sleep. If no change in RMR is observed, playing music during an RMR test could be a potential strategy to prevent participants from falling asleep. Participants will undergo RMR measurements while listening to no music, relaxing classical music, and self-selected classical music.


Eligibility criteria: Exclusion Criteria:

* Any metabolic disorder, or significant cardiopulmonary disease
* Taking medications that are known to affect RMR

Primary outcomes:
measure: Daily Resting Metabolic Rate
timeFrame: Participants will be randomized to three consecutive 15-minute trials involving listening to no music, classical music, or self-selected relaxing music. RMR will be measured continuously over each 15 min trial.
Secondary outcomes:
measure: Heart rate
timeFrame: Participants will be randomized to three consecutive 15-minute trials involving listening to no music, classical music, or self-selected relaxing music. Heart rate will be measured continuously over each 15 min trial.
measure: Excited/bored scale
timeFrame: Participants will be randomized to three consecutive 15-minute trials involving listening to no music, classical music, or self-selected relaxing music. Levels of boredom/excitement will be measured at the end of each 15 min trial.
measure: Sleepiness scale
timeFrame: Participants will be randomized to three consecutive 15-minute trials involving listening to no music, classical music, or self-selected relaxing music. Levels of sleepiness will be measured at the end of each 15 min trial.
Other outcomes:
Locations:
city: Norfolk
country: United States
facility: Human Performance Laboratory
state: Virginia
Study officials:
References:
Clinical trial NCT05948163: Caries Risk Assessment in Egyptian Children in Mixed Dentition Stage
Official title: Caries Risk Assessment Using ADA Tool Among A Group of Egyptian Children in Mixed Dentition Stage : A Cross-Sectional Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Caries Risk Assesment
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-07-17
Enrollment: 296
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children aged 6 to 12 years

Brief summary: This study aim to assess the validity of ADA caries risk assessment tool on the Egyptian Children in mixed dentition stage .

Detailed description: Dental caries is the most common chronic disease of childhood that causes health problems such as pain and infection in children reducing their quality of life.

Risk for caries includes physical, biological, environmental, behavioral, and lifestyle-related factors as insufficient fluoride exposure, poor oral hygiene,inappropriate methods of feeding infants, and poorness .

Risk is a probability that an event will occur. Caries Risk Assessment (CRA) is "prediction of future caries based on the diagnosis of current disease by evaluation of risk and protective factors for making evidence-based clinical decisions. Individual risk assessment constitutes the cornerstone of the treatment plan for the management of early childhood caries for pediatric patients. Caries risk assessment should be included in the treatment plan to facilitate The decision-making process concerning preventive care (both home and office) treatment, recall appointments.

An ideal risk assessment model should be inexpensive, easy to use and time efficient with a high degree of accuracy in caries predictive value.

American Dental Association (ADA) is a tool for caries risk assessment and Management , that when modified to meet the needs of an environment Will be of tremendous use in caries risk assessment. The ADA's mission is to help dentists succeed and support the advancement of the health of the public.

Eligibility criteria: Inclusion Criteria:

* Children age range from 6 to 12 years.
* Apparently healthy children.
* Children affected by dental caries.
* Parents acceptance for their children's participation in the study.

Exclusion Criteria:

* Children on long-term medication.

Primary outcomes:
measure: Caries Risk Assessment using ADA
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: